CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products.
Read More…
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Phone315-797-8375
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$955.10 million
Profitability
Miscellaneous
Employees3,100
Next Earnings Date4/22/2020 (Estimated)
OptionableOptionable
CONMED (NASDAQ:CNMD) Frequently Asked Questions
What is CONMED's stock symbol?
CONMED trades on the NASDAQ under the ticker symbol "CNMD."
How often does CONMED pay dividends? What is the dividend yield for CONMED?
CONMED declared a quarterly dividend on Thursday, November 21st. Shareholders of record on Friday, December 13th will be paid a dividend of $0.20 per share on Tuesday, January 7th. This represents a $0.80 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date is Thursday, December 12th. View CONMED's Dividend History.
How were CONMED's earnings last quarter?
CONMED Co. (NASDAQ:CNMD) released its quarterly earnings results on Wednesday, January, 29th. The medical technology company reported $0.90 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.89 by $0.01. The medical technology company earned $264.90 million during the quarter, compared to analyst estimates of $264.83 million. CONMED had a return on equity of 11.18% and a net margin of 3.00%. The firm's quarterly revenue was up 9.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.73 EPS. View CONMED's Earnings History.
When is CONMED's next earnings date?
What guidance has CONMED issued on next quarter's earnings?
CONMED issued an update on its FY20 earnings guidance on Wednesday, January, 29th. The company provided earnings per share guidance of $3.08-3.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.03.
What price target have analysts set for CNMD?
5 analysts have issued 12-month target prices for CONMED's stock. Their forecasts range from $99.00 to $136.00. On average, they anticipate CONMED's stock price to reach $113.00 in the next twelve months. This suggests a possible upside of 15.2% from the stock's current price. View Analyst Price Targets for CONMED.
What is the consensus analysts' recommendation for CONMED?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CONMED.
Has CONMED been receiving favorable news coverage?
Press coverage about CNMD stock has trended very negative on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. CONMED earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the medical technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for CONMED.
Are investors shorting CONMED?
CONMED saw a decline in short interest in January. As of January 31st, there was short interest totalling 847,000 shares, a decline of 17.0% from the January 15th total of 1,020,000 shares. Based on an average trading volume of 257,700 shares, the days-to-cover ratio is currently 3.3 days. Currently, 3.0% of the company's stock are short sold. View CONMED's Current Options Chain.
Who are some of CONMED's key competitors?
Some companies that are related to CONMED include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Insulet (PODD).
What other stocks do shareholders of CONMED own?
Who are CONMED's key executives?
CONMED's management team includes the folowing people:
- Mr. Curt R. Hartman, CEO, Pres & Director (Age 55)
- Mr. Todd W. Garner, Exec. VP & CFO (Age 50)
- Mr. Patrick J. Beyer, Pres of CONMED International (Age 53)
- Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 44)
- Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 44)
Who are CONMED's major shareholders?
CONMED's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (7.60%), Champlain Investment Partners LLC (3.97%), State Street Corp (3.18%), Principal Financial Group Inc. (2.50%), Goldman Sachs Group Inc. (1.79%) and FMR LLC (1.69%). Company insiders that own CONMED stock include Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, John Jed Kennedy, Johonna Marie Pelletier, Luke A Pomilio, Nathan Folkert, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Institutional Ownership Trends for CONMED.
Which institutional investors are selling CONMED stock?
CNMD stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Champlain Investment Partners LLC, Capital Research Global Investors, J. Goldman & Co LP, William Blair Investment Management LLC, Bank of New York Mellon Corp, Goldman Sachs Group Inc. and 361 Capital LLC. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Dirk Kuyper, John Jed Kennedy, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III and Terence M Berge. View Insider Buying and Selling for CONMED.
Which institutional investors are buying CONMED stock?
CNMD stock was acquired by a variety of institutional investors in the last quarter, including AXA, Man Group plc, Bank of Montreal Can, Eagle Asset Management Inc., Renaissance Technologies LLC, Point72 Asset Management L.P., Great West Life Assurance Co. Can and Cubist Systematic Strategies LLC. View Insider Buying and Selling for CONMED.
How do I buy shares of CONMED?
Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is CONMED's stock price today?
One share of CNMD stock can currently be purchased for approximately $98.06.
How big of a company is CONMED?
CONMED has a market capitalization of $2.78 billion and generates $955.10 million in revenue each year. The medical technology company earns $28.62 million in net income (profit) each year or $2.64 on an earnings per share basis. CONMED employs 3,100 workers across the globe.View Additional Information About CONMED.
What is CONMED's official website?
How can I contact CONMED?
CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.
MarketBeat Community Rating for CONMED (NASDAQ CNMD)
MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
